Last reviewed · How we verify
Course B2 +Vin
Course B2 + Vin is a chemotherapy combination regimen that uses vincristine (Vin) alongside other agents to inhibit microtubule formation and induce apoptosis in cancer cells.
Course B2 + Vin is a chemotherapy combination regimen that uses vincristine (Vin) alongside other agents to inhibit microtubule formation and induce apoptosis in cancer cells. Used for Pediatric malignancies (specific indication not publicly detailed).
At a glance
| Generic name | Course B2 +Vin |
|---|---|
| Sponsor | Children's Cancer Group, China |
| Drug class | Chemotherapy combination regimen |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This is a multi-agent chemotherapy regimen developed by the Children's Cancer Group in China for pediatric malignancies. Vincristine is a vinca alkaloid that binds to tubulin and disrupts microtubule dynamics, leading to cell cycle arrest and apoptosis. The 'Course B2' component likely refers to a standardized protocol sequence that may include additional chemotherapy agents, though the exact composition is not publicly detailed in standard references.
Approved indications
- Pediatric malignancies (specific indication not publicly detailed)
Common side effects
- Peripheral neuropathy
- Myelosuppression
- Nausea and vomiting
- Alopecia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Course B2 +Vin CI brief — competitive landscape report
- Course B2 +Vin updates RSS · CI watch RSS
- Children's Cancer Group, China portfolio CI